Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences

BackgroundThe human IGF2-P4 and H19 promoters are highly active in a variety of human cancers (including bladder cancer), while existing at a nearly undetectable level in the surrounding normal tissue.Single promoter vectors expressing diphtheria toxin A-fragment (DTA) under the control regulation of IGF2-P4 or H19 regulatory sequences (IGF2-P4-DTA and H19-DTA) were previously successfully used in cell lines, animal models and recently in human patients with superficial cell carcinoma of the bladder (treated with H19-DTA). However this targeted medicine approach could be limited, as not all cancer patients express high levels of H19. Hence, a double promoter DTA-expressing vector was created, carrying on a single construct two separate genes expressing the diphtheria toxin A-fragment (DTA), from two different regulatory sequences, selected from the cancer-specific promoters H19 and IGF2-P4.MethodsH19 and IGF2-P4 gene expression was tested in samples of Transitional Cell Carcinoma (TCC) of the bladder by in-situ hybridization (ISH) and by quantitative Real-Time PCR (qRT-PCR). The therapeutic potential of the double promoter toxin vector H19-DTA-IGF2-P4-DTA was tested in TCC cell lines and in heterotopic and orthotopic animal models of bladder cancer.ResultsNearly 100% of TCC patients highly expressed IGF2-P4 and H19, as determined by ISH and by qRT-PCR. The double promoter vector exhibited superior tumor growth inhibition activity compared to the single promoter expression vectors, in cell lines and in heterotopic and orthotopic bladder tumors.ConclusionsOur findings show that bladder tumors may be successfully treated by intravesical instillation of the double promoter vector H19-DTA-P4-DTA.Overall, the double promoter vector exhibited enhanced anti-cancer activity relative to single promoter expression vectors carrying either gene alone.

[1]  L. Tentori,et al.  Recent approaches to improve the antitumor efficacy of temozolomide. , 2009, Current medicinal chemistry.

[2]  M. Cooper.  Noninfectious gene transfer and expression systems for cancer gene therapy. , 1996, Seminars in oncology.

[3]  Maciej Szymanski,et al.  The non-coding RNAs as riboregulators , 2001, Nucleic Acids Res..

[4]  M. Imamura,et al.  Possible paracrine mechanism of insulin‐like growth factor‐2 in the development of liver metastases from colorectal carcinoma , 1999, Cancer.

[5]  S. Wilczynski,et al.  Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors , 1998, Cell and Tissue Research.

[6]  A. Hochberg,et al.  The imprinted H19 gene as a tumor marker in bladder carcinoma. , 1995, Urology.

[7]  Y. M. Lee,et al.  Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. , 1999, Cancer research.

[8]  R. Ohlsson,et al.  Normal development and neoplasia: the imprinting connection. , 1995, The International journal of developmental biology.

[9]  K. Mislick,et al.  Evidence for the role of proteoglycans in cation-mediated gene transfer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  W. Catalona,et al.  Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guérin. , 1984, Cancer research.

[11]  Mitch Dowsett,et al.  Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer , 2008, Clinical Cancer Research.

[12]  A. Hochberg,et al.  The H19 Non-Coding RNA Is Essential for Human Tumor Growth , 2007, PloS one.

[13]  D. Katsaros,et al.  Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. , 2006, Gynecologic oncology.

[14]  Y. Fujita-Yamaguchi,et al.  Promoter usage for insulin-like growth factor-II in cancerous and benign human breast, prostate, and bladder tissues, and confirmation of a 10th exon. , 2000, Biochemical and biophysical research communications.

[15]  R. A. van der Kammen,et al.  Differential expression of the human insulin-like growth factor II gene. Characterization of the IGF-II mRNAs and an mRNA encoding a putative IGF-II-associated protein. , 1988, Biochimica et biophysica acta.

[16]  G. Brewer,et al.  The RNA-binding Protein IMP-3 Is a Translational Activator of Insulin-like Growth Factor II Leader-3 mRNA during Proliferation of Human K562 Leukemia Cells* , 2005, Journal of Biological Chemistry.

[17]  A. Hochberg,et al.  Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. , 1998, Molecular pathology : MP.

[18]  T. Sohda,et al.  Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[19]  J. Sussenbach,et al.  Identification and initial characterization of a fourth leader exon and promoter of the human IGF-II gene. , 1990, Biochimica et biophysica acta.

[20]  M. Hashida,et al.  Disposition and gene expression characteristics in solid tumors and skeletal muscle after direct injection of naked plasmid DNA in mice. , 2003, Journal of pharmaceutical sciences.

[21]  A. Hoffman,et al.  A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. , 2003, The Journal of clinical investigation.

[22]  G. Veenstra,et al.  Differential expression of the human, mouse and rat IGF-II genes , 1993, Regulatory Peptides.

[23]  G. Kouraklis.  Gene therapy for cancer: from the laboratory to the patient. , 2000, Digestive diseases and sciences.

[24]  O. Gofrit,et al.  Regulatory sequences of the H19 gene in DNA based therapy of bladder cancer , 2004 .

[25]  I. Maxwell,et al.  Expression of diphtheria toxin A-chain in mature B-cells: a potential approach to therapy of B-lymphoid malignancy. , 1992, Leukemia & lymphoma.

[26]  A. Hochberg,et al.  The expression of the H19 gene and its function in human bladder carcinoma cell lines , 1999, FEBS letters.

[27]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[28]  Y. Fujita-Yamaguchi,et al.  A quantitative reverse transcription and polymerase chain reaction assay for human IGF-II allows direct comparison of IGF-II mRNA levels in cancerous breast, bladder, and prostate tissues. , 2000, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[29]  R. Goldberg,et al.  First-line therapeutic strategies in metastatic colorectal cancer. , 2008, Oncology.

[30]  A. Hochberg,et al.  Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  A. Irie.  Advances in gene therapy for bladder cancer. , 2003, Current gene therapy.

[32]  R. Weksberg,et al.  Relaxation of imprinting of human insulin-like growth factor II gene, IGF2, in sporadic breast carcinomas. , 1997, Biochemical and biophysical research communications.

[33]  A. Hochberg,et al.  The Oncofetal H19 RNA in human cancer, from the bench to the patient , 2005 .

[34]  W. Engström,et al.  Transcriptional regulation and biological significance of the insulin like growth factor II gene , 1998, Cell proliferation.

[35]  Yunbo Shi,et al.  Novel double promoter approach for identification of transgenic animals: A tool for in vivo analysis of gene function and development of gene‐based therapies , 2002, Molecular reproduction and development.

[36]  C. Polychronakos,et al.  Parental genomic imprinting of the human IGF2 gene , 1993, Nature Genetics.

[37]  A. Reeve,et al.  Insulin-like growth factor 2 and overgrowth: molecular biology and clinical implications. , 1998, Molecular medicine today.

[38]  V. Erdmann,et al.  The product of the imprinted H19 gene is an oncofetal RNA. , 1997, Molecular pathology : MP.

[39]  T. Ekström,et al.  Promoter-specific IGF2 imprinting status and its plasticity during human liver development. , 1995, Development.

[40]  A. Hochberg,et al.  The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma , 2000, Molecular pathology : MP.

[41]  M. Pazin,et al.  An enhancer deletion affects both H19 and Igf2 expression. , 1995, Genes & development.

[42]  D. Lamm,et al.  Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. , 2008, The Journal of urology.

[43]  K. Pavelić,et al.  The Role of Insulin-Like Growth Factor 2 and Its Receptors in Human Tumors , 2002, Molecular medicine.

[44]  A. Hochberg,et al.  The oncofetal H19 RNA connection: hypoxia, p53 and cancer. , 2010, Biochimica et biophysica acta.